Michel Delforge

7PUBLICATIONS
42CO-AUTHORS
Medical mycologyHumoural immunology and immunochemistryPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 13, 2026
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study.

|May 14, 2026
Confirmation of monotypic immunofluorescence staining by mass spectrometry in a case of proliferative glomerulonephritis.

|Apr 27, 2026
Belgian recommendations for tissue diagnosis of amyloidosis.

|Jan 21, 2026
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?

Finn Segers, Michel Delforge

|Mar 24, 2025
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.

Jill Corre, Laure Vincent, Philippe Moreau

|Feb 10, 2025
Suspect the unexpected: proliferative glomerulonephritis with monoclonal immunoglobulin deposits and a negative hematological work-up. A case of monoclonal gammopathy of renal significance.

Benoît Delforge, Elien Mahieu, Amélie Dendooven

Pageof 2

Frequent Collaborators

3 joint publications

Amélie Dendooven

2 joint publications

Frédéric Rousseau

2 joint publications

Simon Devos

2 joint publications

Jill Corre